EPISODE · Feb 9, 2026 · 35 MIN
Getting Practical About Optimizing Management of Stage II and III NSCLC: Expert Guidance to Elevate Care
from CME in Minutes: Education in Oncology & Hematology · host Answers in CME
Please visit answersincme.com/860/97150451-replay4 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD; Kristin Higgins, MD and Nicolas Girard, MD, PhD. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss real-world learner questions to provide evidence-based strategies for applying immunotherapy in resectable and unresectable NSCLC, with practical guidance tailored to everyday clinical challenges. Upon completion of this activity, participants should be better able to: Outline multidisciplinary approaches to optimize perioperative and consolidation IO-based treatment strategies in patients with early-stage NSCLC; and Integrate patient-centered care into the management of early-stage NSCLC.
What this episode covers
Please visit answersincme.com/860/97150451-replay4 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD; Kristin Higgins, MD and Nicolas Girard, MD, PhD. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss real-world learner questions to provide evidence-based strategies for applying immunotherapy in resectable and unresectable NSCLC, with practical guidance tailored to everyday clinical challenges. Upon completion of this activity, participants should be better able to: Outline multidisciplinary approaches to optimize perioperative and consolidation IO-based treatment strategies in patients with early-stage NSCLC; and Integrate patient-centered care into the management of early-stage NSCLC.
NOW PLAYING
Getting Practical About Optimizing Management of Stage II and III NSCLC: Expert Guidance to Elevate Care
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m
Nov 12, 2025 ·35m
Oct 17, 2025 ·40m